Patents by Inventor Yuanbo QIN
Yuanbo QIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230323456Abstract: A polynucleotide, comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region set forth in SEQ ID NO: 2, 3, 4, 20, 51, 68, 144, 148, 152, 162, 164, or 167 in the expression regulatory region of human DUX4 gene is expected to be useful for treating or preventing facioscapulohumeral muscular dystrophy (FSHD).Type: ApplicationFiled: August 31, 2021Publication date: October 12, 2023Applicant: MODALIS THERAPEUTICS CORPORATIONInventors: Tetsuya YAMAGATA, Yuanbo QIN, Rebecca WINDMUELLER
-
Publication number: 20230279374Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.Type: ApplicationFiled: November 25, 2022Publication date: September 7, 2023Applicants: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATIONInventors: Osamu NUREKI, Hiroshi NISHIMASU, Hisato HIRANO, Shohei KAJIMOTO, Tetsuya YAMAGATA, Yuanbo QIN, Keith M. CONNOLLY, Iain THOMPSON
-
Publication number: 20230173036Abstract: The present invention aims to provide a novel therapeutic approach to human muscular dystrophy (particularly MDC1A). The present invention provide a polynucleotide comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) abase sequence encoding (i) a guide RNA targeting continuous region set forth in SEQ ID NO: 15, 20, 25, 50, 56, or 61, (ii) a guide RNA targeting a continuous region set forth in SEQ ID NO: 124, or (iii) a guide RNA targeting a continuous region set forth in SEQ ID NO: 178, 193, or 195, in the expression regulatory region of human LAMA1 gene.Type: ApplicationFiled: August 14, 2020Publication date: June 8, 2023Applicant: Modalis Therapeutics CorporationInventors: Yuanbo QIN, Tetsuya YAMAGATA
-
Patent number: 11591621Abstract: The present invention provides a method of treating a disease associated with elevated KRAS activity or expression in a subject, comprising suppressing KRAS expression in the subject by targeting an expression regulatory region of KRAS gene using a CRISPR-Guide Nucleotide Directed Modulation (GNDM). Also, provided is a CRISPR-GNDM system for suppressing KRAS expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB), and (b) a guide nucleotide targeting an expression regulatory region of KRAS gene.Type: GrantFiled: February 7, 2018Date of Patent: February 28, 2023Assignee: Modalis Therapeutics CorporationInventors: Tetsuya Yamagata, Yuanbo Qin, Haruhiko Morita, Talha Akbulut, Iain Robert Thompson
-
Patent number: 11530396Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.Type: GrantFiled: September 5, 2018Date of Patent: December 20, 2022Assignees: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATIONInventors: Osamu Nureki, Hiroshi Nishimasu, Hisato Hirano, Shohei Kajimoto, Tetsuya Yamagata, Yuanbo Qin, Keith M. Connolly, Iain Thompson
-
Patent number: 11473071Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.Type: GrantFiled: May 14, 2021Date of Patent: October 18, 2022Assignees: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATIONInventors: Eiji Yoshimi, Katsuro Yoshioka, Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Nidhi Khanna
-
Patent number: 11439692Abstract: The present invention provides a method of treating a disease associated with activated MYD88 signaling in a subject, including suppressing MYD88 expression in a subject by targeting an expression regulatory region of MYD88 gene by using a CRISPR-Guide Nucleotide Directed Modulation (GNDM), without affecting the expression of an adjacent ACAA1 gene. Also, provided is a CRISPR-GNDM system for suppressing MYD88, including expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB) and (b) a guide RNA (gRNA) targeting an expression regulatory region of MYD88 gene.Type: GrantFiled: May 17, 2018Date of Patent: September 13, 2022Assignee: Modalis Therapeutics CorporationInventors: Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Haruhiko Morita
-
Publication number: 20220017881Abstract: A protein having a binding ability to guide RNA and consisting of a sequence containing an amino acid sequence wherein a continuous deletion region is present between the 481-position and the 649-position in the amino acid sequence shown in SEQ ID NO: 2, the deletion region containing (i) all or a part of L1 domain (481- to 519-positions), and (ii) entire HNH domain (520- to 628-positions), and further optionally containing (iii) all or a part of L2 domain (629- to 649-positions), wherein amino acids adjacent to each of the deletion region are linked by a linker consisting of 3 to 10 amino acid residues functions as a miniaturized dSaCas9 protein while maintaining DNA binding affinity. Use of the miniaturized dSaCas9 protein makes it possible to mount many genes into vectors.Type: ApplicationFiled: June 7, 2019Publication date: January 20, 2022Applicant: MODALIS THERAPEUTICS CORPORATIONInventors: Tetsuya YAMAGATA, Yuanbo QIN
-
Publication number: 20210355464Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.Type: ApplicationFiled: May 14, 2021Publication date: November 18, 2021Applicants: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATIONInventors: Eiji YOSHIMI, Katsuro YOSHIOKA, Tetsuya YAMAGATA, Yuanbo QIN, Iain Robert THOMPSON, Nidhi KHANNA
-
Publication number: 20210332094Abstract: The present invention provides a transcription activator consisting of not more than 200 amino acid sequences and containing VP64 and a transcription activation site of RTA. The present invention also provides a complex of a nucleic acid sequence-recognizing module specifically binding to a target nucleotide sequence in a double-stranded DNA and the transcription activator.Type: ApplicationFiled: August 6, 2019Publication date: October 28, 2021Applicant: MODALIS THERAPEUTICS CORPORATIONInventors: Tetsuya YAMAGATA, Yuanbo QIN
-
Publication number: 20210260170Abstract: The present invention provides a method of treating a disease associated with activated MYD88 signaling in a subject, including suppressing MYD88 expression in a subject by targeting an expression regulatory region of MYD88 gene by using a CRISPR-Guide Nucleotide Directed Modulation (GNDM), without affecting the expression of an adjacent ACAA1 gene. Also, provided is a CRISPR-GNDM system for suppressing MYD88, including expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB) and (b) a guide RNA (gRNA) targeting an expression regulatory region of MYD88 gene.Type: ApplicationFiled: May 17, 2018Publication date: August 26, 2021Inventors: Tetsuya YAMAGATA, Yuanbo QIN, lain Robert THOMPSON, Haruhiko MORITA
-
Publication number: 20210246473Abstract: The present invention relates to a protein having a binding ability to guide RNA and consisting of a sequence comprising an amino acid sequence wherein a continuous deletion region is present between the 721-position and the 755-position in the amino acid sequence shown in SEQ ID NO: 2, wherein amino acids adjacent to each of the deletion region are linked by a linker consisting of 3 to 10 amino acid residues. The binding ability to the guide RNA, and further, the DNA binding affinity, are maintained even though the protein has a deletion region and is smaller than the full-length dSaCas9. Use of the miniaturized dSaCas9 protein makes it possible to mount many genes into vectors.Type: ApplicationFiled: October 24, 2019Publication date: August 12, 2021Applicant: MODALIS THERAPEUTICS CORPORATIONInventor: Yuanbo QIN
-
Publication number: 20210163907Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.Type: ApplicationFiled: September 5, 2018Publication date: June 3, 2021Applicants: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATIONInventors: Osamu NUREKI, Hiroshi NISHIMASU, Hisato HIRANO, Shohei KAJIMOTO, Tetsuya YAMAGATA, Yuanbo QIN, Keith M. CONNOLLY, Iain THOMPSON
-
Publication number: 20190376088Abstract: The present invention provides a method of treating a disease associated with elevated KRAS activity or expression in a subject, comprising suppressing KRAS expression in the subject by targeting an expression regulatory region of KRAS gene using a CRISPR-Guide Nucleotide Directed Modulation (GNDM). Also, provided is a CRISPR-GNDM system for suppressing KRAS expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB), and (b) a guide nucleotide targeting an expression regulatory region of KRAS gene.Type: ApplicationFiled: February 7, 2018Publication date: December 12, 2019Applicant: EdiGENE CorporationInventors: Tetsuya YAMAGATA, Yuanbo QIN, Haruhiko MORITA, Talha AKBULUT, lain Robert THOMPSON